Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9126 |
High Similarity |
NPD940 |
Approved |
0.9126 |
High Similarity |
NPD846 |
Approved |
0.9029 |
High Similarity |
NPD1242 |
Phase 1 |
0.8889 |
High Similarity |
NPD4750 |
Phase 3 |
0.8641 |
High Similarity |
NPD2859 |
Approved |
0.8641 |
High Similarity |
NPD2860 |
Approved |
0.8571 |
High Similarity |
NPD3020 |
Approved |
0.8544 |
High Similarity |
NPD2933 |
Approved |
0.8544 |
High Similarity |
NPD2934 |
Approved |
0.8286 |
Intermediate Similarity |
NPD844 |
Approved |
0.8214 |
Intermediate Similarity |
NPD3022 |
Approved |
0.8214 |
Intermediate Similarity |
NPD3021 |
Approved |
0.8158 |
Intermediate Similarity |
NPD7635 |
Approved |
0.8145 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.8113 |
Intermediate Similarity |
NPD1809 |
Phase 2 |
0.8095 |
Intermediate Similarity |
NPD845 |
Approved |
0.808 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8037 |
Intermediate Similarity |
NPD288 |
Approved |
0.8036 |
Intermediate Similarity |
NPD2342 |
Discontinued |
0.8019 |
Intermediate Similarity |
NPD1432 |
Clinical (unspecified phase) |
0.7982 |
Intermediate Similarity |
NPD289 |
Clinical (unspecified phase) |
0.7934 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.792 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7899 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7857 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7805 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7805 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7778 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7698 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.767 |
Intermediate Similarity |
NPD111 |
Approved |
0.7623 |
Intermediate Similarity |
NPD4589 |
Approved |
0.7619 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7603 |
Intermediate Similarity |
NPD5304 |
Approved |
0.7603 |
Intermediate Similarity |
NPD3091 |
Approved |
0.7603 |
Intermediate Similarity |
NPD5303 |
Approved |
0.7576 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.7541 |
Intermediate Similarity |
NPD4093 |
Discontinued |
0.7538 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7538 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7538 |
Intermediate Similarity |
NPD943 |
Approved |
0.7519 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD3028 |
Approved |
0.75 |
Intermediate Similarity |
NPD6671 |
Approved |
0.75 |
Intermediate Similarity |
NPD3092 |
Approved |
0.75 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.748 |
Intermediate Similarity |
NPD3019 |
Approved |
0.748 |
Intermediate Similarity |
NPD4059 |
Approved |
0.748 |
Intermediate Similarity |
NPD2286 |
Discontinued |
0.748 |
Intermediate Similarity |
NPD2932 |
Approved |
0.7479 |
Intermediate Similarity |
NPD2228 |
Approved |
0.7479 |
Intermediate Similarity |
NPD2234 |
Approved |
0.7479 |
Intermediate Similarity |
NPD2229 |
Approved |
0.7462 |
Intermediate Similarity |
NPD6407 |
Approved |
0.7462 |
Intermediate Similarity |
NPD6405 |
Approved |
0.7458 |
Intermediate Similarity |
NPD6124 |
Clinical (unspecified phase) |
0.7436 |
Intermediate Similarity |
NPD1792 |
Phase 2 |
0.7424 |
Intermediate Similarity |
NPD2568 |
Approved |
0.7422 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7422 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7405 |
Intermediate Similarity |
NPD1555 |
Discontinued |
0.7402 |
Intermediate Similarity |
NPD4339 |
Clinical (unspecified phase) |
0.7402 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7391 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.7379 |
Intermediate Similarity |
NPD9089 |
Approved |
0.736 |
Intermediate Similarity |
NPD1201 |
Approved |
0.7339 |
Intermediate Similarity |
NPD5238 |
Clinical (unspecified phase) |
0.7339 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7333 |
Intermediate Similarity |
NPD7159 |
Clinical (unspecified phase) |
0.7328 |
Intermediate Similarity |
NPD1444 |
Approved |
0.7328 |
Intermediate Similarity |
NPD1445 |
Approved |
0.7295 |
Intermediate Similarity |
NPD7325 |
Clinical (unspecified phase) |
0.7282 |
Intermediate Similarity |
NPD9093 |
Approved |
0.7273 |
Intermediate Similarity |
NPD1476 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7273 |
Intermediate Similarity |
NPD497 |
Approved |
0.7273 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7266 |
Intermediate Similarity |
NPD1164 |
Approved |
0.7266 |
Intermediate Similarity |
NPD1134 |
Approved |
0.7266 |
Intermediate Similarity |
NPD1135 |
Approved |
0.7266 |
Intermediate Similarity |
NPD1131 |
Approved |
0.7266 |
Intermediate Similarity |
NPD1133 |
Approved |
0.7266 |
Intermediate Similarity |
NPD1129 |
Approved |
0.7259 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7259 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.7259 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7259 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7259 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7252 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7244 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7244 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7239 |
Intermediate Similarity |
NPD3552 |
Approved |
0.7239 |
Intermediate Similarity |
NPD3553 |
Approved |
0.7239 |
Intermediate Similarity |
NPD3555 |
Approved |
0.7239 |
Intermediate Similarity |
NPD3554 |
Approved |
0.7217 |
Intermediate Similarity |
NPD9500 |
Approved |
0.7214 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.72 |
Intermediate Similarity |
NPD1751 |
Approved |
0.72 |
Intermediate Similarity |
NPD3095 |
Discontinued |
0.719 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.719 |
Intermediate Similarity |
NPD498 |
Approved |
0.719 |
Intermediate Similarity |
NPD496 |
Approved |
0.719 |
Intermediate Similarity |
NPD495 |
Approved |
0.7177 |
Intermediate Similarity |
NPD2226 |
Clinical (unspecified phase) |
0.7177 |
Intermediate Similarity |
NPD7330 |
Discontinued |
0.7168 |
Intermediate Similarity |
NPD9273 |
Approved |
0.7167 |
Intermediate Similarity |
NPD228 |
Approved |
0.7165 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7164 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7164 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7132 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7132 |
Intermediate Similarity |
NPD1470 |
Approved |
0.7132 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7109 |
Intermediate Similarity |
NPD4659 |
Approved |
0.7077 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7059 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.7055 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7054 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7031 |
Intermediate Similarity |
NPD2561 |
Approved |
0.7031 |
Intermediate Similarity |
NPD2562 |
Approved |
0.7023 |
Intermediate Similarity |
NPD5736 |
Approved |
0.7015 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7009 |
Intermediate Similarity |
NPD9608 |
Approved |
0.7009 |
Intermediate Similarity |
NPD9610 |
Approved |
0.7 |
Intermediate Similarity |
NPD4103 |
Phase 2 |
0.7 |
Intermediate Similarity |
NPD3053 |
Approved |
0.7 |
Intermediate Similarity |
NPD4104 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD3055 |
Approved |
0.7 |
Intermediate Similarity |
NPD9380 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD5451 |
Approved |
0.6984 |
Remote Similarity |
NPD5691 |
Approved |
0.6984 |
Remote Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.6984 |
Remote Similarity |
NPD4235 |
Clinical (unspecified phase) |
0.6984 |
Remote Similarity |
NPD1651 |
Approved |
0.6978 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6977 |
Remote Similarity |
NPD1669 |
Approved |
0.6972 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.6972 |
Remote Similarity |
NPD7447 |
Phase 1 |
0.6972 |
Remote Similarity |
NPD9094 |
Approved |
0.6967 |
Remote Similarity |
NPD9377 |
Approved |
0.6967 |
Remote Similarity |
NPD9379 |
Approved |
0.6963 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6963 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6953 |
Remote Similarity |
NPD5351 |
Clinical (unspecified phase) |
0.6953 |
Remote Similarity |
NPD5350 |
Clinical (unspecified phase) |
0.6947 |
Remote Similarity |
NPD2194 |
Approved |
0.6947 |
Remote Similarity |
NPD2195 |
Approved |
0.6947 |
Remote Similarity |
NPD599 |
Approved |
0.6947 |
Remote Similarity |
NPD859 |
Approved |
0.6947 |
Remote Similarity |
NPD858 |
Approved |
0.6947 |
Remote Similarity |
NPD602 |
Approved |
0.6942 |
Remote Similarity |
NPD9280 |
Clinical (unspecified phase) |
0.6935 |
Remote Similarity |
NPD709 |
Approved |
0.6929 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6929 |
Remote Similarity |
NPD3750 |
Approved |
0.6923 |
Remote Similarity |
NPD5700 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD5310 |
Approved |
0.6923 |
Remote Similarity |
NPD1283 |
Approved |
0.6923 |
Remote Similarity |
NPD5311 |
Approved |
0.6917 |
Remote Similarity |
NPD5155 |
Approved |
0.6917 |
Remote Similarity |
NPD5156 |
Approved |
0.6917 |
Remote Similarity |
NPD2684 |
Approved |
0.6901 |
Remote Similarity |
NPD7213 |
Phase 3 |
0.6901 |
Remote Similarity |
NPD7212 |
Phase 2 |
0.6899 |
Remote Similarity |
NPD2232 |
Approved |
0.6899 |
Remote Similarity |
NPD2233 |
Approved |
0.6899 |
Remote Similarity |
NPD2230 |
Approved |
0.6894 |
Remote Similarity |
NPD3636 |
Approved |
0.6894 |
Remote Similarity |
NPD3635 |
Approved |
0.6894 |
Remote Similarity |
NPD3637 |
Approved |
0.6891 |
Remote Similarity |
NPD968 |
Approved |
0.6875 |
Remote Similarity |
NPD1980 |
Approved |
0.6875 |
Remote Similarity |
NPD1981 |
Approved |
0.6875 |
Remote Similarity |
NPD3026 |
Approved |
0.6875 |
Remote Similarity |
NPD1983 |
Approved |
0.6875 |
Remote Similarity |
NPD3143 |
Discontinued |
0.6875 |
Remote Similarity |
NPD3023 |
Approved |
0.687 |
Remote Similarity |
NPD2797 |
Approved |
0.6855 |
Remote Similarity |
NPD1793 |
Approved |
0.6855 |
Remote Similarity |
NPD1791 |
Approved |
0.685 |
Remote Similarity |
NPD3024 |
Approved |
0.685 |
Remote Similarity |
NPD3025 |
Approved |
0.6849 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6846 |
Remote Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.6846 |
Remote Similarity |
NPD6582 |
Phase 2 |
0.6846 |
Remote Similarity |
NPD6583 |
Phase 3 |
0.6842 |
Remote Similarity |
NPD2606 |
Approved |
0.6842 |
Remote Similarity |
NPD2605 |
Approved |
0.6835 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD3540 |
Phase 1 |
0.6835 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6829 |
Remote Similarity |
NPD5535 |
Approved |
0.6825 |
Remote Similarity |
NPD856 |
Approved |
0.6825 |
Remote Similarity |
NPD16 |
Approved |
0.6824 |
Remote Similarity |
NPD7819 |
Suspended |
0.6818 |
Remote Similarity |
NPD3690 |
Phase 2 |
0.6818 |
Remote Similarity |
NPD3691 |
Phase 2 |
0.6818 |
Remote Similarity |
NPD4624 |
Approved |
0.6815 |
Remote Similarity |
NPD6663 |
Approved |
0.6812
|
Remote Similarity |
NPD3299 |
Clinical (unspecified phase) |